SEC Comment Letter for ProPhase Labs, Inc. (PRPH) (CIK 0000868278) (PRPH) — Jul 3, 2018
ProPhase Labs, Inc. (PRPH) (CIK 0000868278)
Date: July 3, 2018 · CIK: 0000868278 · Accession: 0000000000-18-020460
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225875
Letter
July 2, 2018 Ted Karkus Chief Executive Officer ProPhase Labs, Inc. 621 N. Shady Retreat Road Doylestown, PA 18901 Re:ProPhase Labs, Inc. Registration Statement on Form S-3 Filed June 25, 2018 File No. 333-225875 Dear Mr. Karkus: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Wendy Grasso
Show Raw Text
July 2, 2018
Ted Karkus
Chief Executive Officer
ProPhase Labs, Inc.
621 N. Shady Retreat Road
Doylestown, PA 18901
Re:ProPhase Labs, Inc.
Registration Statement on Form S-3
Filed June 25, 2018
File No. 333-225875
Dear Mr. Karkus:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Wendy Grasso